Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Work In Process (2021 - 2025)

Mirum Pharmaceuticals (MIRM) has 5 years of Work In Process data on record, last reported at $18.5 million in Q4 2025.

  • For Q4 2025, Work In Process rose 14.82% year-over-year to $18.5 million; the TTM value through Dec 2025 reached $18.5 million, up 14.82%, while the annual FY2025 figure was $18.5 million, 14.82% up from the prior year.
  • Work In Process reached $18.5 million in Q4 2025 per MIRM's latest filing, up from $18.3 million in the prior quarter.
  • Across five years, Work In Process topped out at $18.5 million in Q4 2025 and bottomed at $553000.0 in Q1 2022.
  • Average Work In Process over 5 years is $10.2 million, with a median of $10.5 million recorded in 2023.
  • Peak YoY movement for Work In Process: skyrocketed 1072.51% in 2023, then rose 14.82% in 2025.
  • A 5-year view of Work In Process shows it stood at $570000.0 in 2021, then skyrocketed by 838.77% to $5.4 million in 2022, then skyrocketed by 84.51% to $9.9 million in 2023, then skyrocketed by 62.96% to $16.1 million in 2024, then rose by 14.82% to $18.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Work In Process were $18.5 million in Q4 2025, $18.3 million in Q3 2025, and $16.3 million in Q2 2025.